Synlogic appoints Michael Jensen as CFO effective March 3, 2022

SYNLOGIC, INC.

Michael Jensen named CFO; previously CFO at Intrinsic Therapeutics and Taconic Biosciences.
Base salary $395K, bonus target 40%, option grant of 230K shares at $2.23, 30K RSUs.
Employment agreement provides 6-month severance upon termination without cause or for good reason.
Press release notes Synlogic on track to start Phase 3 study for PKU in H2 2022.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Jensen

Chief Financial Officer

SYBX · SYNLOGIC, INC.

Effective: 2022-03-03
Filed: March 3, 2022, 6:59 PM ET

On March 3, 2022, Synlogic, Inc. (the “Company”) announced the appointment of Michael Jensen as Chief Financial Officer, effective March 3, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Jensen was appointed as Chief Financial Officer at SYNLOGIC, INC..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On March 3, 2022, Synlogic, Inc. (the “Company”) announced the appointment of Michael Jensen as Chief Financial Officer, effective March 3, 2022.

View on SEC.gov

SYNLOGIC, INC. filing history →

Source: SEC EDGAR

accession 0001193125-22-064445

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.